Public Plans
Public plans are plans created using the DMP Tool service and shared publicly by their owners. They are not vetted for quality, completeness, or adherence to funder guidelines.
Plans (113)
NIH Data Management and Sharing Plan (2026 Pilot DMS Format)
CMV driven Immune Pressures on HIV-1 Immunity: Effects on immune response and reservoir dynamics(CIPHI)
Amanda Green, St. Jude Children's Research Hospital (stjude.org)
NIH Data Management and Sharing Plan (2026 Pilot DMS Format)
Development of a Low-Cost Multi-Omic Screening Assay for Detection of Early-Stage Uterine Serous and Other High-Grade Endometrial Carcinomas from Pap Specimens
Thomas Pisanic, Johns Hopkins University (jhu.edu)
NIH Data Management and Sharing Plan (2026 Pilot DMS Format)
Cognitive and Arousal Mechanisms Linking Sleep and Internalizing Psychopathology in College Students: A Prospective, Multi-Method Study
Emily Bartholomay, University of Nebraska at Kearney (unk.edu)
NIH Data Management and Sharing Plan (2026 Pilot DMS Format)
Translational control of Rb by NDRG1 in VHL-null renal cell carcinoma
Travis Salisbury, Marshall University (marshall.edu)
NIH DMS Plan Format 2023 Version (Allowed for due dates prior to May 25th, 2026)
Effectiveness and Safety of Metformin Extended-Release Compared with Glipizide in Patients with Uncontrolled Type 2 Diabetes Mellitus: A Phase III Double-Blind Randomized Controlled Trial
Nindara citra Aquarista, Universitas Gadjah Mada (ugm.ac.id)
NIH DMS Plan Format 2023 Version (Allowed for due dates prior to May 25th, 2026)
Efektivitas dan Keamanan Metformin Extended-Release dibandingkan Glipizide pada Pasien Diabetes Tipe 2
Ansgaria Asa, Universitas Gadjah Mada (ugm.ac.id)
NIH DMS Plan Format 2023 Version (Allowed for due dates prior to May 25th, 2026)
Prenatal environmental co-exposures and child circadian and sleep health
Natalie Binczewski, Duke University (duke.edu)
NIH DMS Plan Format 2023 Version (Allowed for due dates prior to May 25th, 2026)
Fatty acid Nitroalkene inhibition of LRRK2 hyperactivation and oxidative stress in Parkinson's disease
Marco Fazzari, University of Pittsburgh (pitt.edu)
NIH DMS Plan Format 2023 Version (Allowed for due dates prior to May 25th, 2026)
VT-109-001: Phase 1 Randomized, Double-Blind, Placebo-Controlled SAD/MAD Study of VT-109 in Healthy Adults
Akram Khan, Oregon Health & Science University (ohsu.edu)
